Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immuneering CorpIMRX · Entity 5884 | Director | June 11, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immuneering Corp
Report date June 11, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2036-06-11 | Direct | 33,350 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 33,350 · Balance 33,350 F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 11, 2026 21:29 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001790340-26-000068 · wk-form4_1781213381.xml · derivative · entry 1 CARPENTER ROBERT J · CIK 0001021046 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2036-06-11 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 11, 2026, and will be fully vested and exercisable on June 11, 2027, or the date of the 2027 annual meeting of stockholders, whichever comes first. Read SEC document |
| June 13, 2025 Filed Jun 16, 2025 12:59 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001790340-25-000067 · wk-form4_1750078761.xml · derivative · entry 1 CARPENTER ROBERT J · CIK 0001021046 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2035-06-13 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:21 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 33,350 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001628280-24-028061 · wk-form4_1718310074.xml · derivative · entry 1 CARPENTER ROBERT J · CIK 0001021046 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,350 Underlying: Class A Common Stock · 33,350 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 12, 2024, and will be fully vested and exercisable on June 12, 2025, or the date of the 2025 annual meeting of stockholders, whichever comes first. Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:30 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 17,500 | $0.00 Strike: $9.32 | $0.00 |
DisclosureSEC source: 0001790340-23-000033 · wk-form4_1686860993.xml · derivative · entry 1 CARPENTER ROBERT J · CIK 0001021046 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Class A Common Stock · 17,500 shares Expires 2033-06-14 F1 · derivative.exercise_date: The option vests and becomes exercisable in substantially equal monthly installments over a one-year period with a vesting commencement date of June 14, 2023, and will be fully vested and exercisable on June 14, 2024, or the date of the 2024 annual meeting of stockholders, whichever comes first. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 21:00 UTC | Immuneering Corp IMRX · Entity 5884 | GrantStock Option · Derivative | 14,200 | $0.00 Strike: $4.63 | $0.00 |
DisclosureSEC source: 0001415889-22-006898 · form4-06232022_020624.xml · derivative · entry 1 CARPENTER ROBERT J · CIK 0001021046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,200 Underlying: Class A Common Stock · 14,200 shares Expires 2032-06-20 F1 · derivative.exercise_date: The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 21, 2022, and will be fully vested and exercisable on June 21, 2023, or the date of the 2023 annual meeting of stockholders, whichever comes first. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:05 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries B Preferred Stock · Derivative | 122,588 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099732 · tm2123807-5_4seq.xml · derivative · entry 4 CARPENTER ROBERT J · CIK 0001021046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 122,588 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:05 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionSeries A Preferred Stock · Derivative | 94,585 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099732 · tm2123807-5_4seq.xml · derivative · entry 3 CARPENTER ROBERT J · CIK 0001021046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 94,585 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:05 UTC | Immuneering Corp IMRX · Entity 5884 | PurchaseClass A Common Stock | 325,000 | $15.00 | $4,875,000.00 |
DisclosureSEC source: 0001104659-21-099732 · tm2123807-5_4seq.xml · nonDerivative · entry 2 CARPENTER ROBERT J · CIK 0001021046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,839 Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 10:05 UTC | Immuneering Corp IMRX · Entity 5884 | ConversionClass A Common Stock | 217,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-099732 · tm2123807-5_4seq.xml · nonDerivative · entry 1 CARPENTER ROBERT J · CIK 0001021046 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 823,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.